---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000154"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:44:43.345363+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zentalis Q2 cash $553M; azenosertib ORR 36.8% with RP2D set

## Summary
- Cash, equivalents and marketable securities $553.0M as of June 30, 2023; runway into 2026.
- Azenosertib monotherapy ORR 36.8% in ovarian cancer/USC; RP2D set at 400 mg QD 5:2.
- Phase 1b azenosertib + paclitaxel ORR 50.0% (mPFS 7.4 mo); + carboplatin ORR 35.7% (mPFS 10.4 mo).
- Q2 R&D expense $42.7M, G&A $15.7M; one-time Zentera termination charge $45.6M.
- Closed $250M public offering (11.03M shares at $22.66) in June; appointed CSO Kimberly Freeman.

## SEC filing metadata
- accession: 0001725160-23-000154
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000154/0001725160-23-000154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000154/zntl-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000154
- JSON: https://secwatch.observer/filing/0001725160-23-000154.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000154.txt

## Key facts
- Earnings Releases
  Zentalis Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000154/0001725160-23-000154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.